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Hepatic ﬁbrosis is the common end point to chronic injury of var-
ied aetiology. There is now excellent evidence in both human
studies and animal models that liver ﬁbrosis is a bidirectional
process with a signiﬁcant reversible component. The hepatic stel-
late cell (HSC), following activation to a myoﬁbroblast phenotype,
is the principal cell producing extracellular matrix (ECM) during
ﬁbrogenesis and is the main source of TIMP-1, which inhibits the
endogenous matrix-degrading activity of matrix metalloprotein-
ases (MMPs), thus promoting scar deposition. Furthermore, apop-
tosis of activated HSCs is a critical feature of scar resolution.
However, emerging evidence indicates that it is the hepatic mac-
rophage that is the master regulator of this dynamic ﬁbrogene-
sis–ﬁbrosis resolution paradigm.Macrophages can promote ﬁbrogenesis
The key role of macrophages in promoting hepatic ﬁbrogenesis
has been demonstrated in a number of studies. Transgenic ani-
mals, deﬁcient in the principal macrophage chemokine CCL2-
CCR2 axis [1], show reduced monocyte/macrophage inﬁltration
following chronic hepatic injury and are protected from ﬁbrogen-
esis. Furthermore, utilising a CD11b-DTR system in mice, selec-
tive depletion of macrophages during ongoing injury causes a
reduction in ﬁbrosis [2]. Additional work has identiﬁed a speciﬁc
Gr-1high subset of hepatic macrophages, derived from recruit-
ment of inﬂammatory monocytes in a CCR2-dependent manner,
as being the principal pro-ﬁbrotic population [3].
So how do macrophages mediate this effect? Closer analysis of
ﬁbrotic tissue in human disease and animal models identiﬁes
macrophages closely associated with the hepatic scar, directly
apposed to the activated HSCs. Macrophages are a rich source
of soluble mediators which can act on the HSCs to induce a
pro-ﬁbrotic phenotype. Speciﬁcally, macrophages can produceJournal of Hepatology 20
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Open access under CC BY-NC-ND license.and activate the archetypal pro-ﬁbrotic cytokine TGF-b, which
acts to increase myoﬁbroblast ECM and TIMP-1 production [3].
Additionally, hepatic macrophages can produce PDGF (a potent
stimulator of myoﬁbroblast proliferation), IL-1b and TNF-a
(pro-inﬂammatory cytokines) and a number of chemokines
which can induce further inﬂammatory cell recruitment to per-
petuate the pro-inﬂammatory pro-ﬁbrotic stimulus [4] (Fig. 1).Macrophages are critical for ﬁbrosis resolution
Emerging evidence now clearly demonstrates that macrophages
also have a pivotal role in ﬁbrosis resolution. Selective depletion
of hepatic macrophages during the spontaneous recovery phase
after chronic CCl4-induced ﬁbrosis caused a clear failure of hepa-
tic scar remodelling [2]. Additionally, in CCR2 knockout mice,
despite a lower baseline ﬁbrotic response, there is diminished
ﬁbrosis resolution following the cessation of injury [1]. Finally,
the administration of exogenous macrophages during ongoing
hepatic injury can have a signiﬁcant anti-ﬁbrotic effect [5].
The mechanisms governing the role of the macrophage in
ﬁbrosis resolution are still not fully deﬁned and are likely to be
multi-factorial, given the immense plasticity in macrophage phe-
notypes. We have previously shown that macrophages are a rich
source of scar degrading MMPs, particularly MMP-13, during the
resolution phase in vivo [6]. Macrophages are also capable of pro-
ducing a number of factors, such as MMP-9 or TRAIL, which can
promote HSC apoptosis, although a functional role for this mech-
anism remains to be proven. Additionally, loss of the pro-inﬂam-
matory pro-ﬁbrotic signals expressed by macrophages during
ﬁbrogenesis might alter the local milieu to favour ﬁbrosis resolu-
tion. Indeed, in elegant work by the Tacke group, they deﬁned
that CX3CL1 produced by hepatocytes and HSCs in the inﬂamed
liver could signal to inﬁltrating monocyte-derived macrophages
via the CX3CR1 receptor, inducing macrophage survival and an
anti-inﬂammatory phenotype to limit the degree of hepatic
inﬂammation and ﬁbrosis [7]. Macrophages in inﬂamed tissue
also perform the phagocytosis of cellular debris, which removes
potential pro-inﬂammatory signals and may in turn alter macro-
phage phenotype causing increased MMP expression and
enhanced matrix degradation [8]. Furthermore, in renal ﬁbrosis
studies serum amyloid P (SAP) protein, a circulating serum pro-
tein, binds to apoptotic cells, opsonising them and then signalling
via Fcc receptors on monocytes and macrophages, inducing an12 vol. 56 j 1417–1419
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Fig. 1. Macrophages: Central regulators of hepatic ﬁbrogenesis and ﬁbrosis resolution.
Hepatology Snapshotanti-inﬂammatory phenotype with increased IL-10 production
and consequent protection from ﬁbrosis [9] (Fig. 1).The identity of the pro-resolution macrophage
Clearly, macrophages can show signiﬁcant functional differences
in their effects on hepatic ﬁbrosis. It is well described that mac-
rophage populations are heterogeneous in the ﬁbrotic liver, with
distinct contributions from resident Kupffer cells and recruited
monocytes [2]. Indeed, signiﬁcant macrophage heterogeneity
has been identiﬁed by ﬂow cytometry analysis of freshly-isolated
human liver, with a CD14+ CD16+ population accumulating in the
ﬁbrotic liver and correlating with worsening ﬁbrosis [10]. How-
ever, what remains elusive is the identity of the macrophage sub-
set mediating ﬁbrosis resolution. Speciﬁcally, do pro-resolution
macrophages derive from resident or recruited cells? Does local
macrophage proliferation contribute to the formation of distinct
populations? Are they formed from pro-ﬁbrotic macrophages
by a phenotypic switch in situ? What factors induce this switch?
What genes do they express to mediate their effect? Answers to
these questions in animal models will also permit identiﬁcation
and characterisation of pro-resolution macrophages in situ in
the human cirrhotic liver. Furthermore, a greater understanding1418 Journal of Hepatology 2012will enable the development of novel therapeutic strategies to
manipulate macrophage phenotype in vivo and accelerate ﬁbrosis
resolution.Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Mitchell C, Couton D, Couty JP, Anson M, Crain AM, Bizet V, et al. Dual role of
CCR2 in the constitution and the resolution of liver ﬁbrosis in mice. Am J
Pathol 2009;174:1766–1775.
[2] Dufﬁeld JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al.
Selective depletion of macrophages reveals distinct, opposing roles during
liver injury and repair. J Clin Invest 2005;115:56–65.
[3] Karlmark KR, Weiskirchen R, Zimmermann HW, Gassler N, Ginhoux F, Weber
C, et al. Hepatic recruitment of the inﬂammatory Gr1+ monocyte subset
upon liver injury promotes hepatic ﬁbrosis. Hepatology 2009;50:261–274.
[4] Wynn TA, Barron L. Macrophages: master regulators of inﬂammation and
ﬁbrosis. Semin Liver Dis 2010;30:245–257.
[5] Thomas JA, Pope C, Wojtacha D, Robson AJ, Gordon-Walker TT, Hartland S,
et al. Macrophage therapy for murine liver ﬁbrosis recruits host effector cellsvol. 56 j 1417–1419
JOURNAL OF HEPATOLOGY
improving ﬁbrosis, regeneration, and function. Hepatology
2011;53:2003–2015.
[6] Fallowﬁeld JA, Mizuno M, Kendall TJ, Constandinou CM, Benyon RC, Dufﬁeld
JS, et al. Scar-associated macrophages are a major source of hepatic matrix
metalloproteinase-13 and facilitate the resolution of murine hepatic ﬁbrosis.
J Immunol 2007;178:5288–5295.
[7] Karlmark KR, Zimmermann HW, Roderburg C, Gassler N, Wasmuth HE,
Luedde T, et al. The fractalkine receptor CXCR1 protects against liver ﬁbrosis
by controlling differentiation and survival of inﬁltrating hepatic monocytes.
Hepatology 2010;52:1769–1782.
[8] Popov Y, Sverdlov DY, Bhaskar KR, Sharma AK, Millonig G, Patsenker E, et al.
Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributesJournal of Hepatology 2012to reversal of experimental biliary ﬁbrosis. Am J Physiol Gastrointest Liver
Physiol 2010;298:G323–G334.
[9] Castano AP, Lin SL, Surowy T, Nowlin BT, Turlapati SA, Patel T, et al. Serum
amyloid P inhibits ﬁbrosis through Fc gamma R-dependent monocyte-
macrophage regulation in vivo. Sci Transl Med 2009;1:5ra13.
[10] Zimmermann HW, Seidler S, Nattermann J, Gassler N, Hellerbrand C,
Zernecke A, et al. Functional contribution of elevated circulating and hepatic
non-classical CD14CD16 monocytes to inﬂammation and human liver
ﬁbrosis. PLoS One 2010;5:e11049.vol. 56 j 1417–1419 1419
